Vernalis Share Price (VER)

18.75 -0.25 (-1.32%) delayed: 11:30AM BST
Bid price 18.25 Open price 18.25
Ask price 19.25 Prev close 19.00
High price 18.25 Spread 5.19%
Low price 18.42 Volume 140,451

Register now for FREE live Vernalis share prices, Vernalis stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Vernalis Level 2 Data, indepth research tools and investor commentary for Vernalis (VER) and other London Stock Exchange equities.

Vernalis Share Price Chart

Advanced Charts >>

Register now for FREE Vernalis share price charts

Vernalis Share Price Information

Name Vernalis Epic VER
Sector Pharmaceuticals & Biotechnology ISIN GB00B3Y5L754
Activites Vernalis plc (formerly British Biotech) is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as seven programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris. Index n/a

Vernalis Key Numbers

Latest Share Price (p) 18.75 Net Gearing (%) 2.43
Market Capitalisation (£m) 100.03 Gross Gearing (%) 8.68
Shares in issue (m) 526.45 Debt Ratio 1.96
P/E Ratio -5.94 Debt-to-Equity Ratio 0.21
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.10
Dividend Yield (%) 0.00 Price to book value 0.97
Dividend cover (x) 0.00 ROCE (%) -14.60
Earning per share (p) -3.20 EPS Growth (%) -128.57
52 week high / low 51.50 / 16.00 DPS Growth (%) n/a

Vernalis Director Deals

Dec.Date Type Director Pos No. of Shares
12/10/2016 EXR David Mackney FD 48,630
12/10/2016 SEXR David Mackney FD 27,233
12/10/2016 EXR Ian Garland CEO 91,310
09/06/2016 BUY Ian Garland CEO 245,000
09/06/2016 BUY David Mackney FD 97,000

More Vernalis Director Deals >>

Vernalis Company News

07:00 18/07/2017

Year-End Trading Update and Notice of Results

RNS Number : 2825L Vernalis PLC 18 July 2017   18 July 2017 LSE: VER Year-End Trading Update and Notice of Full Year Results Continued steady growth of Tuzistra® XR annualised prescription run rate through drug's second cough cold season; similar growth rate expected...

07:11 18/07/2017

Vernalis anticipates sales to be expectations

Vernalis said total revenues are expected to be ahead of current market expectations. This was principally as a result of larger than expected research collaboration milestones. With better than expected total operating costs due to careful cost control, the resulting operating loss is expected...

07:00 30/06/2017

Total Voting Rights

RNS Number : 6343J Vernalis PLC 30 June 2017   TOTAL VOTING RIGHTS   VERNALIS PLC (the "Company")   30 June 2017   Vernalis plc (LSE: VER) announces that the Company's total issued share capital at the date of this announcement is 526,445,230 ordinary...

More Vernalis Company News >>

Register now for FREE Vernalis company news

Vernalis Share Price Discussions

more than 1 year ago

New Vernalis (VER)

This is for 2008 -9 (2007 was a year with great hopes and hype, equals a sp about 50p) Reality now is a sp about 4p Yet despite a drug failure ( was it?), they have some products that look interesting - not earth-shattering but a decent pipeline AND some CASH - "wow"! the only Q in my mind: Is...

more than 1 year ago

Vernalis- Judgment day on 30/9/07 (VER)

Surely the answer from FDA is going to be yes!

Register now for FREE Vernalis share price discussions